GHRP-6 vs Ipamorelin
Written by the Pure Peptides editorial team
Reviewed by Dr. Martina Rossi, PhD
Scientific Contributor and Reviewer · Reviewed
Published · Updated · 16 references
GHRP-6 and Ipamorelin are two different molecules: GHRP-6 is a synthetic six-residue peptide, and Ipamorelin is a synthetic five-residue peptide.
Structure at a glance
GHRP-6 · 6 residues
Ipamorelin · 5 residues
NH2: C-terminal amide. A raised D marks a D-amino acid. 2Nal: 2-naphthylalanine. Aib: alpha-aminoisobutyric acid. Codes are three-letter amino acid codes.
Drawn from the product database. Each measure's bars share one scale.
| Property | GHRP-6 | Ipamorelin |
|---|---|---|
| What it is | A synthetic six-residue peptide with a free N-terminal amine and a C-terminal amide. | A synthetic five-residue peptide that does not correspond to any natural peptide sequence. |
| How they relate | Different molecules. GHRP-6 is a synthetic hexapeptide in which two of the six residues are D-configured. Ipamorelin is a synthetic pentapeptide containing non-natural and D-configured amino acids, including alpha-aminoisobutyric acid. | |
| CAS number | 87616-84-0 | 170851-70-4 |
| Molecular formula | C46H56N12O6 | C38H49N9O5 |
| Molecular weight | 873.01 g/mol | 711.85 g/mol |
| Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 | Aib-His-D-2Nal-D-Phe-Lys-NH2 |
| Evidence base | More than 80 published human studies, mostly single-dose; repeated use lasted a week at most.[13] Published controlled trials with a clinical outcome gave it with epidermal growth factor; the larger missed its primary endpoint.[14] | Three published human studies. One was a pharmacokinetic-pharmacodynamic study in healthy male volunteers.[2] A randomized phase 2 trial missed its key endpoint and its secondary analyses.[3] The third tracked its breakdown products in one volunteer's urine.[11] |
| Regulatory status | The FDA has not approved GHRP-6 for human use. | The FDA has not approved Ipamorelin for human use. |
| Compared head-to-head? | Yes: a 1998 study tested GHRP-6 and Ipamorelin in conscious swine.[4] The paper came from Ipamorelin's developer.[4] A 2000 study tested each in young adult female rats.[5] Further comparisons found in PubMed (searched October 2026).[6] | |
| Handling difference | Neither contains cysteine or methionine. GHRP-6 carries two tryptophans, which can oxidize. Ipamorelin's aromatic side chains can also oxidize. | |
How GHRP-6 and Ipamorelin differ
GHRP-6 and Ipamorelin are different molecules. GHRP-6 is a synthetic six-residue peptide with a free N-terminal amine and a C-terminal amide. Ipamorelin is a synthetic five-residue peptide that does not correspond to any natural peptide sequence. Two of GHRP-6's six residues are D-configured, and it carries two tryptophans. Ipamorelin contains non-natural and D-configured amino acids, including alpha-aminoisobutyric acid and a D-configured naphthylalanine.
More than 80 published studies have given GHRP-6 to people, most of them single-dose tests; published studies of repeated use lasted a week at most.[13] The published controlled trials with a clinical outcome gave it together with epidermal growth factor, and the larger one missed its primary endpoint.[14] ClinicalTrials.gov lists no trial of GHRP-6.[1] The Cuban public registry lists at least seven, and no results have been located for four of them.[15] An author of the 1990 human study of GHRP-6 held an inventor interest.[7] The literature reviewed for GHRP-6 reports no serious safety finding from its human studies.
The literature reviewed for Ipamorelin includes three published human studies. One was an early-phase pharmacokinetic-pharmacodynamic study in healthy male volunteers.[2] The other was a randomized phase 2 trial of 114 participants, in one indication, and it missed its key endpoint and its secondary analyses.[3] The third, a 2015 anti-doping laboratory study, tracked its breakdown products in one volunteer's urine for two days.[11] Almost everything else known about Ipamorelin comes from preclinical pharmacology. Much of the defining preclinical work on Ipamorelin comes from its original developer, which raises the usual question of independent replication. FDA's 2024 review of the phase 2 trial records serious adverse events in 10 of 56 patients given Ipamorelin and 9 of 58 given placebo.[12] Two patients given Ipamorelin died after colon cancer surgery complicated by a leak where the bowel was rejoined.[12] FDA states it is unclear whether the deaths were related to Ipamorelin.[12]
The FDA has not approved either GHRP-6 or Ipamorelin for human use.
Neither peptide contains cysteine, methionine, asparagine, glutamine or aspartate. GHRP-6's two tryptophan indoles can oxidize on exposure to air, light and trace metals. Heated in solution, GHRP-6 degraded by C-terminal deamidation, hydrolysis and head-to-tail cyclization, and oxidized tryptophan forms were minor.[16] In Ipamorelin, the remaining routes are general. Its amide bonds hydrolyze under strong acid or alkali, slowly near neutral pH, and its aromatic side chains can oxidize. Each is cationic and carries aromatic rings, so each can adsorb to surfaces both electrostatically and hydrophobically. In each, mass spectrometry cannot verify the configuration of the D-residues, since a D-residue and its L-form are identical in mass.
Have GHRP-6 and Ipamorelin been compared directly?
A 1998 study tested GHRP-6 and Ipamorelin in conscious swine.[4] The paper came from Ipamorelin's developer.[4] A 2000 study tested each in young adult female rats.[5] A 2001 study tested each in mice.[8] A 2002 study tested each in vitro, in pituitary cell cultures from young female rats given one of three pretreatments.[9] A 2009 study tested each in a rat surgical model.[10] Results are reported for each compound in each paper.
Read more on each compound
GHRP-6
Frequently Asked Questions
Is GHRP-6 the same as Ipamorelin?+−
GHRP-6 and Ipamorelin are different molecules: GHRP-6 is a synthetic six-residue peptide, and Ipamorelin is a synthetic five-residue peptide. GHRP-6 has two D-configured residues and carries two tryptophans. Ipamorelin contains non-natural and D-configured amino acids, including alpha-aminoisobutyric acid.
References
- 1ClinicalTrials.gov v2 API, per-compound queries by intervention and general term, 27 August 2026. GHRP-6 returns zero registered studies, as it still did on 16 October 2026.
- 2Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharm Res. 1999;16(9):1412-6. doi:10.1023/a:1018955126402. PMID 10496658.
- 3Beck DE, Sweeney WB, McCarter MD. 2014;29(12):1527-1534. doi:10.1007/s00384-014-2030-8. PMID 25331030.
- 5Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. J Endocrinol. 2000;165(3):569-577. PMID 10828840.
- 6
PubMed search, 3 October 2026 (records to 2 October 2026)
22 records, including the 5 direct comparisons described above.
Exact query (NCBI E-utilities): ("GHRP-6"[tiab] OR "GHRP 6"[tiab] OR "GHRP6"[tiab] OR "growth hormone-releasing peptide-6"[tiab] OR "growth hormone releasing peptide-6"[tiab] OR "growth hormone releasing peptide 6"[tiab]) AND ("ipamorelin"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])
View this search on PubMed - 8Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Biochem Biophys Res Commun. 2001;280(1):132-138. PMID 11162489.
- 9Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. Histol Histopathol. 2002;17(3):707-714. PMID 12168778.
- 10Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. J Pharmacol Exp Ther. 2009;329(3):1110-1116. PMID 19289567.
- 11Semenistaya E, Zvereva I, Thomas A, Thevis M, Krotov G, Rodchenkov G. Drug Test Anal. 2015;7(10):919-25. doi:10.1002/dta.1787. PMID 25869809. Anti-doping laboratory study.
- 12US Food and Drug Administration, Center for Drug Evaluation and Research. Briefing document, 29 October 2024, section on clinical studies assessing safety. Regulatory document, not peer-reviewed. fda.gov
- 13PubMed searches via NCBI E-utilities, run 16 October 2026, for GHRP-6 under its name variants and its sequence. Limited to clinical trial and clinical study publication types: 56 records, 38 of them giving GHRP-6 to people. Limited to humans: 322 records, 97 giving it to people. Some describe the same participants.
- 14Hernández-Bernal F, Subirós-Martínez N, Gutiérrez-Ronquillo JH, et al. J Clin Neurosci. 2026;152:112195. doi:10.1016/j.jocn.2026.112195. PMID 42462342. Randomized, open-label phase III trial; primary endpoint not met.
- 15WHO International Clinical Trials Registry Platform search portal, searches run 16 October 2026: at least seven interventional trials of the same peptide in the Cuban Public Registry of Clinical Trials, registered from 2010 to 2026 under its name and under its sponsor's code. No results were located for four of them.

Reviewed for scientific accuracy
Dr. Martina Rossi, PhD
PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer
Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.
Related comparisons
CJC-1295 (No DAC) vs Ipamorelin
CJC-1295 (No DAC) is a synthetic peptide built on human GHRH's first 29 residues; Ipamorelin is a synthetic five-residue peptide.
Read ComparisonGHRP-2 vs GHRP-6
GHRP-2 and GHRP-6 are different molecules: six-residue peptides differing in composition, including how many residues are D-configured.
Read ComparisonIpamorelin vs Sermorelin
Ipamorelin is a five-residue peptide; Sermorelin is the 29-residue N-terminal fragment of human GHRH.
Read Comparison

